SLC7A5 and liver cancer: Unexpectedly, one group reported that pharmacological inhibition and genomic mutation of LAT1 does not abolish cell growth or mTORC1 activity in liver cancer cell lines, indicating the possibility of cell-line-specific compensation or a large reserve capacity [32].